Back

Effect of the magnitude of LDL lowering on the incidence of cataract among patients treated with statins or PCSK9 antibodies

29 August 2017 (17:06 - 17:24)
Organised by:
Congress Presentation Part of: Cholesterol-lowering therapy for primary and secondary prevention Lipids (Epidemiology and Prevention) ESC Premium Access ESC Congress 2017

About the speaker

Photo
Professor John B Kostis

Rutgers Robert Wood Johnson Medical School, New Brunswick (United States of America)

4 More presentations in this session

Presentation thumbnail
State of the Art: cholesterol-lowering therapy for primary and secondary prevention
Doctor J. Robinson (Iowa, US)
Slides Video
Presentation thumbnail
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes mellitus: a systematic review and meta-analysis with over 10,000 patients
Doctor L. Carvalho (Brasilia, BR)
Abstract Slides Video
Presentation thumbnail
Comparison of the low-density lipoprotein cholesterol target value and the preventive effect of statins in elderly patients and younger patients
Doctor A. Endo (Izumo, JP)
Abstract Slides Video
Presentation thumbnail
Lipid-lowering therapy in primary prevention: where will we be 10 years from now
Professor A. Catapano (Milan, IT)

Access the full session

Session thumbnail
Cholesterol-lowering therapy for primary and secondary prevention

The Event

Event poster

ESC Congress 2017

29 August 2017 17:06 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources